Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

Video

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the role of CAR T-cell therapy in multiple myeloma.

BCMA-targeted CAR T-cell therapies have shown unprecedented response rates and depth of response in patients with heavily pretreated relapsed/refractory multiple myeloma, says Voorhees.

Unlike B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, CAR T-cell therapy has not shown curative potential in multiple myeloma, says Voorhees.

The investigational CAR T-cell therapy, bb2121 (idecabtagene vicleucel), demonstrated a median progression-free survival (PFS) of 11.8 months (95% CI, 6.2-17.8) in patients with heavily pretreated relapsed/refractory disease in the phase I CRB-401 study (NCT02658929). Though patients will progress on this treatment, 1-year PFS in this setting is highly encouraging, explains Voorhees.

Moving CAR T-cell therapy into earlier lines of treatment may elicit more durable responses, says Voorhees. Additionally, CAR T-cell therapy may have the potential to overcome high-risk disease in patients who do not respond well to initial therapy, or in those who relapse after frontline treatment, concludes Voorhees.

Recent Videos
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Related Content
© 2025 MJH Life Sciences

All rights reserved.